Investigational drug abemaciclib shows durable clinical activity for variety of cance

[News]

The investigational anticancer therapeutic abemaciclib, which targets CDK4 and CDK6, showed durable clinical activity when given as continuous single-agent therapy to patients with a variety of cancer types, including breast cancer, non-small cell lung cancer (NSCLC), glioblastoma, and melanoma, according to results from a phase I clinical trial.

More... (http://www.news-medical.net/news/20160523/Investigational-drug-abemaciclib-shows-durable-clinical-activity-for-variety-of-cancer-types.aspx)